{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mismatch+Repair+Deficient+%28dMMR%29&page=2", "query": { "condition": "Mismatch Repair Deficient (dMMR)", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mismatch+Repair+Deficient+%28dMMR%29&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-22T01:53:02.801Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03050814", "title": "Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Tumors", "Colorectal Neoplasms", "Colorectal Carcinoma", "Colorectal Adenocarcinoma", "Colorectal Cancer" ], "interventions": [ { "name": "Avelumab", "type": "DRUG" }, { "name": "Ad-CEA vaccine", "type": "BIOLOGICAL" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "5-Fluorouracil (FU)", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2017-04-05", "completion_date": "2021-08-25", "has_results": true, "last_update_posted_date": "2021-12-20", "last_synced_at": "2026-07-22T01:53:02.801Z", "location_count": 2, "location_summary": "Washington D.C., District of Columbia • Bethesda, Maryland", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03050814" }, { "nct_id": "NCT02992964", "title": "Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Refractory or Recurrent Hypermutated Malignancies", "Biallelic Mismatch Repair Deficiency (bMMRD) Positive Patients" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Hospital for Sick Children", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "18 Years", "sex": "ALL", "summary": "12 Months to 18 Years" }, "enrollment_count": 11, "start_date": "2017-05-15", "completion_date": "2023-11-20", "has_results": false, "last_update_posted_date": "2024-04-02", "last_synced_at": "2026-07-22T01:53:02.801Z", "location_count": 2, "location_summary": "Boston, Massachusetts • Philadelphia, Pennsylvania", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02992964" }, { "nct_id": "NCT04439214", "title": "Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Lymphoma", "Advanced Malignant Solid Neoplasm", "Hematopoietic and Lymphoid Cell Neoplasm", "Refractory Lymphoma", "Refractory Malignant Solid Neoplasm", "Refractory Plasma Cell Myeloma" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2016-05-31", "completion_date": "2020-05-17", "has_results": true, "last_update_posted_date": "2021-04-06", "last_synced_at": "2026-07-22T01:53:02.801Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04439214" }, { "nct_id": "NCT03050268", "title": "Familial Investigations of Childhood Cancer Predisposition", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Acute Leukemia", "Adenomatous Polyposis", "Adrenocortical Carcinoma", "AML", "BAP1 Tumor Predisposition Syndrome", "Carney Complex", "Choroid Plexus Carcinoma", "Constitutional Mismatch Repair Deficiency Syndrome", "Diamond-Blackfan Anemia", "DICER1 Syndrome", "Dyskeratosis Congenita", "Emberger Syndrome", "Familial Acute Myeloid Leukemia", "Familial Adenomatous Polyposis", "Fanconi Anemia", "Familial Cancer", "Familial Wilms Tumor", "Familial Neuroblastoma", "GIST", "Hereditary Breast and Ovarian Cancer", "Hereditary Paraganglioma-Pheochromocytoma Syndrome", "Hodgkin Lymphoma", "Juvenile Polyposis", "Li-Fraumeni Syndrome", "Lynch Syndrome", "MDS", "Melanoma Syndrome", "Multiple Endocrine Neoplasia Type 1", "Multiple Endocrine Neoplasia Type 2", "Neuroblastoma", "Neurofibromatosis Type 1", "Neurofibromatosis Type II", "Nevoid Basal Cell Carcinoma Syndrome", "Non Hodgkin Lymphoma", "Noonan Syndrome and Other Rasopathy", "Overgrowth Syndromes", "Pancreatic Cancer", "Peutz-Jeghers Syndrome", "Pheochromocytoma/Paraganglioma", "PTEN Hamartoma Tumor Syndrome", "Retinoblastoma", "Rhabdoid Tumor Predisposition Syndrome", "Rhabdomyosarcoma", "Rothmund-Thomson Syndrome", "Tuberous Sclerosis", "Von Hippel-Lindau Disease" ], "interventions": [], "intervention_types": [], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1500, "start_date": "2017-04-06", "completion_date": "2037-03-31", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-07-22T01:53:02.801Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03050268" }, { "nct_id": "NCT05838768", "title": "Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers" ], "interventions": [ { "name": "HRO761", "type": "DRUG" }, { "name": "pembrolizumab", "type": "BIOLOGICAL" }, { "name": "irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 123, "start_date": "2023-06-27", "completion_date": "2027-08-31", "has_results": false, "last_update_posted_date": "2026-03-24", "last_synced_at": "2026-07-22T01:53:02.801Z", "location_count": 6, "location_summary": "Los Angeles, California • San Francisco, California • Boston, Massachusetts + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05838768" }, { "nct_id": "NCT03241745", "title": "A Study of Nivolumab in Selected Uterine Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Uterine Cancer", "Endometrial Carcinoma", "Carcinosarcoma", "Leiomyosarcoma", "Undifferentiated Sarcoma", "High Grade Endometrial Stromal Sarcoma", "Clear Cell Carcinoma" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 35, "start_date": "2017-08-03", "completion_date": "2024-04-01", "has_results": true, "last_update_posted_date": "2024-12-27", "last_synced_at": "2026-07-22T01:53:02.801Z", "location_count": 8, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03241745" }, { "nct_id": "NCT04906382", "title": "Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Lynch Syndrome", "Recurrent Endometrial Carcinoma", "Recurrent Endometrial Clear Cell Adenocarcinoma", "Recurrent Uterine Corpus Carcinosarcoma", "Mismatch Repair Deficiency", "Recurrent Endometrial Cancer", "Metastatic Endometrial Cancer" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Tislelizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "Floor Backes, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 2, "start_date": "2021-07-01", "completion_date": "2022-09-01", "has_results": false, "last_update_posted_date": "2025-02-13", "last_synced_at": "2026-07-22T01:53:02.801Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04906382" }, { "nct_id": "NCT02359565", "title": "Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Constitutional Mismatch Repair Deficiency Syndrome", "Lynch Syndrome", "Malignant Glioma", "Recurrent Brain Neoplasm", "Recurrent Childhood Ependymoma", "Recurrent Diffuse Intrinsic Pontine Glioma", "Recurrent Medulloblastoma", "Refractory Brain Neoplasm", "Refractory Diffuse Intrinsic Pontine Glioma", "Refractory Ependymoma", "Refractory Medulloblastoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Conventional Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Diffusion Tensor Imaging", "type": "PROCEDURE" }, { "name": "Diffusion Weighted Imaging", "type": "PROCEDURE" }, { "name": "Dynamic Contrast-enhanced MR Perfusion", "type": "PROCEDURE" }, { "name": "Dynamic Susceptibility Contrast-Perfusion-Weighted Imaging", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Spectroscopic Imaging", "type": "PROCEDURE" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "30 Years", "sex": "ALL", "summary": "1 Year to 30 Years" }, "enrollment_count": 71, "start_date": "2015-06-03", "completion_date": "2027-01-16", "has_results": false, "last_update_posted_date": "2026-07-20", "last_synced_at": "2026-07-22T01:53:02.801Z", "location_count": 11, "location_summary": "Los Angeles, California • Palo Alto, California • Aurora, Colorado + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02359565" }, { "nct_id": "NCT04165772", "title": "Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rectal Adenocarcinoma", "Clinical Stage: Stage II (T3-4, N-)", "Stage III (Any T, N+)", "Solid Tumor", "Solid Tumor, Adult" ], "interventions": [ { "name": "TSR-042 or Dostarlimab", "type": "DRUG" }, { "name": "capecitabine or 5-FU", "type": "DRUG" }, { "name": "Intensity Modulated Radiation Therapy (IMRT)", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 212, "start_date": "2019-12-11", "completion_date": "2026-11-30", "has_results": false, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-07-22T01:53:02.801Z", "location_count": 10, "location_summary": "Hartford, Connecticut • Miami, Florida • Basking Ridge, New Jersey + 7 more", "locations": [ { "city": "Hartford", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT04165772" }, { "nct_id": "NCT06529523", "title": "Tislelizumab in People With Colorectal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "Tislelizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2024-07-26", "completion_date": "2028-07", "has_results": false, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-07-22T01:53:02.801Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06529523" } ] }